Context: Abdominal visceral adiposity and central sarcopenia are markers of increased cardiovascular risk and mortality.
| INTRODUCTION
Adrenal tumours are found in 5% of patients undergoing abdominal cross-sectional imaging, and most are diagnosed as nonfunctioning benign adrenal cortical adenomas (ACAs). 1, 2 While overt adrenal cortisol excess affects only 0.7%-5% of patients with ACAs, 3, 4 mild autonomous cortisol excess (MACE) is much more prevalent, reported in up to 47% of patients with ACAs. [5] [6] [7] The clinical importance of detecting MACE is debated due to variations in the spectrum of biochemical abnormalities, degree of suppression of the hypothalamic-pituitary-adrenal axis (HPA) and unclear individual prognostic implications. A recent systematic review and meta-analysis revealed that more than 12 unique definitions have been used to define MACE, which include various test combinations, assays and cut-offs. Longitudinal retrospective studies demonstrated that, as a group, patients with MACE had an increased prevalence of cardiovascular risk factors (eg, hypertension, type 2 diabetes mellitus (DM2), obesity and dyslipidemia), which lead to an increased cardiovascular mortality. [8] [9] [10] [11] In comparison with patients managed conservatively, patients
with MACE treated with adrenalectomy demonstrated a reduction in cardiovascular risk factors. 8 However, the selection of patients who might benefit from adrenalectomy is difficult. One of the reasons for this uncertainty is the possibility of false positives, especially when biochemical abnormalities are mild. Another concern is that hypertension, DM2, obesity and dyslipidemia are prevalent in the general population, and yet in an individual patient with MACE, the glucocorticoid secretory autonomy may not be a significant contributor. • Assess baseline differences in abdominal adipose tissue and total muscle mass in patients with nonfunctioning adrenal tumours (NFAT) in comparison with patients with MACE and overt Cushing's syndrome (CS).
• Correlate body composition measurements such as abdominal adiposity and muscle mass with morning serum cortisol concentrations after a 1 mg overnight DST.
| SUBJECTS AND METHODS
We reviewed a retrospective cohort of all patients undergoing ad- 
| Study participants
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Cardiovascular risk factors such as the presence of hypertension, dyslipidemia, prediabetes and DM2 were collected for all patients in the cohort. Hypertension was defined as documented diagnosis of hypertension treated with at least 1 antihypertensive medication.
Composite diabetes included patients with documented diagnosis of either DM2 or prediabetes and therapy with at least 1 glucoselowering medication. Dyslipidemia was defined as documented diagnosis and therapy with at least 1 lipid-lowering medication. 
| Measurements
| Biochemical analysis
| CT Protocol and body composition measurements using BodyCompSlicer analysis program
Computed tomography (CT) imaging of the abdomen was obtained . We calculated: visceral-tosubcutaneous fat ratio (V/S), total fat (VAT + SAT) and visceral-tototal fat ratio (V/T).
| Muscle mass measurements
A wide range of techniques can be used to measure total muscle mass.
However, CT and magnetic resonance imaging (MRI) are considered the gold standard, 22 and cross-sectional areas of tissues in the lumbar area are strong correlates of whole body muscle mass. 23, 24 We measured total abdominal muscle mass on 3 lumbar spine levels (L1-L3)
that included psoas muscle, paraspinal muscles, internal and external oblique, transverse abdominus muscles.
| Statistics
Descriptive statistics were used to determine mean and standard deviation (SD) or median and ranges depending on data distribution, while categorical data are shown as a number (%). Associations between variables were assessed using one-way ANOVA for continuous variables and we adjusted for multiple comparisons using a Bonferroni correction. P values less than .05 were considered significant. Data were analysed using jmp software, version 10 (SAS, Carey, NC, USA).
Baseline differences in body composition measurements in between the 3 groups were performed using linear regression analysis adjusting for age, sex and BMI. Additionally, to investigate the relationship of morning cortisol concentrations after overnight DST and body composition, we performed a multivariate linear regression analyses predicting body composition with cortisol levels while controlling for confounding factors including age, sex and body mass index (BMI).
| RESULTS
| Demographic and endocrine data for all patients with adrenal adenomas
A total of 105 patients with a median age 53 years (range, 18-82) and a female predominance (n = 78, 74%) presented with adrenal tumours of median tumour size of 3.5 cm (range, 1-16). 
| Measurements of visceral and subcutaneous fat area
Unadjusted for confounding factors, no differences were found in baseline measurements of VAT and SAT area between the 3 groups. 
| Measurements of total abdominal muscle mass
Statistically significant abdominal muscle mass differences were noted at baseline between the 3 groups for both unadjusted and adjusted for confounding factors such as age, sex and BMI.
Patients with overt CS had the lowest mean abdominal muscle mass. Mean total muscle mass in patients with CS, MACE and NFAT were 112 vs 133 vs 149 cm 2 , respectively (P = .01).
When adjusted for age, sex and BMI, in comparison with patients with NFAT, total muscle mass was decreased by −10 (P = .02) in patients with overt CS but not in patients with MACE. Similarly, muscle mass/visceral fat was decreased by −0.6 (P = .05) in patients with overt CS compared to NFAT but not in MACE.
| Body composition in relation to morning post-DST cortisol concentrations
We assessed the correlation of body composition measurements with cortisol concentrations after overnight DST after adjusting for age, sex and BMI. For every 28 nmol/L (1 mcg/dL) cortisol increase after overnight DST, we observed an increase of 0.008 in V/T (P < .001), an increase of 0.02 in V/S fat ratio (P < .001) and a decrease of 1.2 cm 
| DISCUSSION
We assessed differences in body composition in patients with adrenal adenomas presenting with varying degrees of cortisol secretion.
We hypothesized that patients with more severe glucocorticoid secretory autonomy/hypercortisolism would demonstrate a higher visceral fat and lower muscle mass. We found that morning cortisol concentrations after overnight DST positively correlated with visceral fat adiposity and negatively correlated with abdominal muscle mass.
Interestingly, when patients with adrenal adenomas were assigned into one of 3 groups based on predefined criteria (overt CS, MACE, NFAT), only patients with overt CS, but not patients with MACE, had higher visceral fat and lower muscle mass when compared to patients with NFAT.
There are several proposed mechanisms for hypercortisolisminduced predominance of visceral to subcutaneous fat tissue development. Glucocorticoid receptors (GR) are found to be more abundant in the VAT compared to SAT. 25 In conditions of hypercortisolism, despite a downregulation in the number of GR in the adipose tissue, the increased GR numbers are thought be responsible for a hypersensitivity of visceral fat adipocytes to cortisol leading to accumulation of visceral adiposity, 26 as seen in patients with Cushing's disease. In the study of Wajchenberg et al 16 in which hypercortisolemic subjects were compared to obese individuals with the same anthropometric values (age, BMI and waist hip ratio), VAT but not SAT was significantly greater in patients with hypercortisolism. Another mechanism explaining predominance of visceral over subcutaneous adipose tissue in patients with hypercortisolism is an increased activity of 11-beta-hydroxyreductase activity in omental fat generating cortisol from the inactive cortisone. 27 Finally, several polymorphisms (ie, NR3C1 and Bc11) in the GC receptor are described that may either increase or decrease GC sensitivity. To what extent these common genetic variants may influence glucocorticoid sensitivity and regional differences in body composition measurements in patients with CS remains to be further investigated. 28 In our study, when we adjusted for major cofounding factors (age, sex and BMI), the V/T fat ratio was increased in patients with overt CS when compared to NFAT which is in agreement with other studies.
16 Surprisingly, we have observed that VAT and V/S were lower in patients with MACE when compared to NFAT. It is possible that patients with NFAT included in our study
were not representative, given our selection from the adrenalectomy cohort, presenting with higher prevalence of metabolic abnormalities and relatively low ACTH levels (median 2.2 pml/L). In addition, the duration of exposure to cortisol excess prior to diagnosis, which was n/a n/a n/a with NFAT compared to healthy controls demonstrate a subtle cortisol hypersecretion and higher risk of DM in patients with NFAT, potentially contributing to inaccuracy of our patient assignment to a specific group. 29, 30 Similarly, in the study of Yener et al, 19 no sig- to be involved such as mTOR, FOXO, GSK3,p300, REDD1 and KLF-15. 17 Our results suggest that even mild hypercortisolism has a measurable effect on abdominal muscle mass contributing to the extent of cortisol-induced body composition abnormalities.
| Strengths and limitations
We acknowledge that this is a retrospective study with its inherent ; however, clinical measurements of adiposity and muscle strength such as waist-to-hip ratio and/or hand grid strength are missing from our study. This was a pilot study demonstrating baseline cortisol-related differences in body composition of patients with ACAs; further larger studies are needed to confirm these results, to assess the correlation of the body composition with cardiovascular risk factors, as well as to evaluate body composition changes after adrenalectomy.
| Clinical implications
It is recognized that visceral obesity increases the risk for dyslipidemia, 36 hypertension 37 and DM2. 38 The mechanisms through which adiposity results in these metabolic abnormalities are not well understood;however, secretion of potentially harmful cytokines (eg, IL-6, TNF-a), 39 excess free fatty acid, increased hepatic gluconeogenesis and lipoprotein production, 26, 40 and reduced release of beneficial adipokines 41 are several proposed explanations.
The cut-off point of abdominal visceral adipose tissue related to increased cardiovascular risk ranges between 110 and 133 cm 2 42-44 and disorders of glucose and lipid metabolism predominate in patients with V/S ratio higher than 0.4. 44 In our cohort, all 3 groups of patients with ACAs demonstrated body composition cut-offs above the reported values suggesting an overall increased cardiovascular risk in all patients with ACAs. Similar to adipose tissue, loss of muscle mass and sarcopenia has been shown to be an independent cardiovascular risk factor and mortality. Performing body composition analysis in a larger sample of wellcharacterized patients with adrenal adenomas, not limited to patients undergoing adrenalectomy, is necessary before transformation of such biomarker into clinical practice.
| CONCLUSION
In conclusion, patients with ACAs demonstrate abnormal body composition measurements that are related to glucocorticoid secretory autonomy. Higher degree of hypercortisolism is associated with lower abdominal muscle mass and higher visceral adiposity. Body composition measurement may provide an additive value in making a diagnosis of clinically important MACE and aid in individualizing management of patients with ACAs and MACE.
